Erschienen in:
15.02.2019 | IM - PHYSICAL EXAMINATION
Hypocalcemia and hypophosphatemia after treatment with zoledronic acid in a patient with AL amyloidosis
verfasst von:
Antonella Tufano, Domenico Rendina, Paolo Conca, Beniamino Matani, Giovanni Di Minno
Erschienen in:
Internal and Emergency Medicine
|
Ausgabe 3/2019
Einloggen, um Zugang zu erhalten
Excerpt
Zoledronic acid (Zol) is the most powerful third generation aminobisphosphonate, can be intravenously (IV) administered, and is commonly used in patients with metabolic and neoplastic bone disorders, including multiple myeloma (MM). Zol reduces osteoclastic activity and promotes cellular apoptosis and can induce both hypocalcemia (HypoCa) and hypophosphatemia (HypoP), usually mild and asymptomatic. The risk of symptomatic severe HypoCa and HypoP, requiring specific treatment, is low, and has been described in patients with additional predisposing risk factors, such as low 25OHD
3, chronic kidney disease (CKD), and/or liver damage [
1‐
3]. …